This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims** 

Claim 1: (Currently Amended) A pharmaceutical preparation comprising active

compound, gelatin and fillers and which is free of organic solvent residues, wherein the active

compound consists essentially of levo-thyroxine sodium, whereby said preparation possesses

improved stability versus one in which a customary binder other than gelatin is used.

Claim 2: (Canceled)

Claim 3: (Previously Presented) The pharmaceutical preparation according to claim 1,

containing 5 to 400 µg of levothyroxine.

Claim 4: (Previously Presented) The pharmaceutical preparation according to claim

1, containing levothyroxine sodium micronized with a particle size of between 5  $\mu m$  and 25  $\mu m$ .

Claim 5: (Previously Presented) The pharmaceutical preparation according to Claim 1,

wherein the filler is lactose, maize starch or microcrystalline cellulose.

Claim 6: (Previously Presented) The pharmaceutical preparation according to Claim 1,

2

which is a solid preparation in the form of tablets.

Claim 7: (Canceled)

Claim 8: (Canceled)

Claim 9: (Currently Amended) A pharmaceutical preparation consisting essentially of levo-thyroxine sodium, gelatin and fillers which is free of organic solvent residues and which is in solid form, whereby said preparation possesses improved stability versus one in which a customary binder other than gelatin is used.

Claim 10: (Currently Amended) A pharmaceutical preparation comprising active compound, gelatin and fillers and which is free of organic solvent residues, wherein the active compound consists essentially of levo-thyroxine sodium and liothyronine sodium, whereby said preparation possesses improved stability versus one in which a customary binder other than gelatin is used.